| Index | — | P/E | — | EPS (ttm) | -3.46 | Insider Own | 1.63% | Shs Outstand | 166.18M | Perf Week | -5.02% |
| Market Cap | 6.85B | Forward P/E | — | EPS next Y | -2.08 | Insider Trans | -8.72% | Shs Float | 162.92M | Perf Month | -5.28% |
| Enterprise Value | 7.22B | PEG | — | EPS next Q | -1.22 | Short Float | 12.68% | Perf Quarter | -25.11% | ||
| Income | -566.00M | P/S | 7.84 | EPS this Y | — | Short Ratio | 6.26 | Perf Half Y | -45.34% | ||
| Sales | 874.00M | P/B | 15.58 | EPS next Y | — | ROA | -18.86% | Short Interest | 20.65M | Perf YTD | -47.87% |
| Book/sh | 2.65 | P/C | 3.34 | EPS next 5Y | — | ROE | -110.84% | 52W High | 86.74 -52.46% | Perf Year | -44.40% |
| Cash/sh | 12.37 | P/FCF | — | EPS past 3/5Y | — | ROIC | -20.37% | 52W Low | 41.19 0.12% | Perf 3Y | -9.62% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 17.16% 5.30% | Gross Margin | 98.16% | Volatility | 4.25% 3.60% | Perf 5Y | 37.01% |
| Dividend TTM | — | EV/Sales | 8.26 | EPS Y/Y TTM | — | Oper. Margin | -68.08% | ATR (14) | 1.77 | Perf 10Y | 46.92% |
| Dividend Ex-Date | — | Quick Ratio | 7.72 | Sales Y/Y TTM | -7.51% | Profit Margin | -64.64% | RSI (14) | 36.32 | Recom | 2.33 |
| Dividend Gr. 3/5Y | — | Current Ratio | 7.88 | EPS Q/Q | -180.23% | SMA20 | -5.72% | Beta | 0.39 | Target Price | 84.92 |
| Payout | 0.00% | Debt/Eq | 5.50 | Sales Q/Q | -40.71% | SMA50 | -15.23% | Rel Volume | 0.81 | Prev Close | 43.52 |
| Employees | 1,480 | LT Debt/Eq | 4.95 | Earnings | Nov 04 | SMA200 | -38.08% | Avg Volume | 3.14M | Price | 41.24 |
| IPO Date | May 17, 1991 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 36.63% 41.73% | Net Debt/EBITDA | — | Volume | 2,553,915 | Change | -5.24% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-22-26 | Upgrade | BMO Capital | Market Perform → Outperform | $66 |
| Oct-20-26 | Reiterated | Raymond James | Strong Buy | $84 → $79 |
| Oct-15-26 | Upgrade | UBS | Neutral → Buy | $38 → $88 |
| Sep-24-26 | Reiterated | Oppenheimer | Outperform | $111 → $85 |
| Sep-15-26 | Reiterated | Guggenheim | Buy | $89 → $80 |
| Sep-09-26 | Reiterated | Barclays | Overweight | $90 → $85 |
| Sep-08-26 | Reiterated | Raymond James | Strong Buy | $87 → $84 |
| Sep-08-26 | Reiterated | Morgan Stanley | Overweight | $110 → $104 |
| Sep-08-26 | Reiterated | Goldman Sachs | Neutral | $69 → $56 |
| Sep-08-26 | Reiterated | BMO Capital | Market Perform | $61 → $54 |
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 874 | 944 | 705 | 788 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 16 | 16 | 11 | 9 | — | — | — | — | — | |
| Gross Profit | 857 | 928 | 694 | 779 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 527 | 394 | 268 | 233 | — | — | — | — | — | |
| Research and Development | 925 | 916 | 902 | 900 | — | — | — | — | — | |
| Other Operating Expense | 2 | 0 | -1 | -1 | — | — | — | — | — | |
| Operating Income | -594 | -382 | -475 | -354 | — | — | — | — | — | |
| Interest Expense | 89 | 91 | 90 | 81 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 123 | 93 | 105 | 101 | — | — | — | — | — | |
| Net Income Before Taxes | -561 | -380 | -460 | -334 | — | — | — | — | — | |
| Income Taxes | 0 | 1 | -6 | 32 | — | — | — | — | — | |
| Consolidated Net Income | -566 | -381 | -454 | -366 | — | — | — | — | — | |
| Net Income From Continuing Operations | -563 | -381 | -454 | -366 | — | — | — | — | — | |
| Net Income | -566 | -381 | -454 | -366 | — | — | — | — | — | |
| EPS (Recurring) | -3.46 | -2.38 | -3.04 | -2.56 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.46 | -2.38 | -3.04 | -2.56 | — | — | — | — | — | |
| EPS (Diluted) | -3.46 | -2.38 | -3.04 | -2.56 | — | — | — | — | — | |
| EBITDA | -480 | -284 | -354 | -236 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.79 | 13.41 | 7.44 | 9.18 | — | — | — | — | — | |
| Gross Margin | 98.05 | 98.31 | 98.44 | 98.86 | — | — | — | — | — | |
| Operating Margin | -67.96 | -40.47 | -67.38 | -44.92 | — | — | — | — | — | |
| Net Margin | -64.76 | -40.36 | -64.40 | -46.45 | — | — | — | — | — | |
| Shares Outstanding | 165 | 160 | 150 | 143 | — | — | — | — | — | |
| Market Capitalization | 6,805 | 12,658 | 5,244 | 7,234 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Devers Shannon L. | EVP, Chief Human Resources Ofc | Oct 16 '26 | Sale | 43.54 | 1,357 | 59,082 | 17,811 | Oct 19 |
| Swayze Eric | EVP Research | Oct 16 '26 | Sale | 43.54 | 53 | 2,308 | 390 | Oct 19 |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | Oct 15 '26 | Option Exercise | 0.00 | 2,820 | 0 | 19,168 | Oct 19 |
| Swayze Eric | EVP Research | Oct 15 '26 | Option Exercise | 0.00 | 125 | 0 | 443 | Oct 19 |
| Hayden Michael R | Director | Jul 31 '26 | Buy | 51.60 | 5,000 | 258,000 | 24,000 | Jul 31 |
| Hayden Michael R | Director | Jul 30 '26 | Buy | 53.38 | 15,000 | 800,700 | 19,000 | Jul 31 |
| HERMAN JOAN E | Director | Jul 15 '26 | Option Exercise | 0.00 | 5,220 | 0 | 51,306 | Jul 17 |
| BERTHELSEN SPENCER R | Director | Jul 15 '26 | Option Exercise | 0.00 | 5,220 | 0 | 161,233 | Jul 17 |
| BENNETT C FRANK | EVP, Chief Scientific Officer | Jul 07 '26 | Sale | 84.95 | 20,536 | 1,744,623 | 0 | Jul 09 |
| Diaz Allene M. | Director | Jul 07 '26 | Option Exercise | 47.11 | 10,111 | 476,329 | 13,922 | Jul 09 |
| Diaz Allene M. | Director | Jul 07 '26 | Sale | 85.42 | 10,111 | 863,637 | 3,811 | Jul 09 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | Jul 07 '26 | Sale | 84.30 | 362 | 30,517 | 22,096 | Jul 09 |
| KLEIN JOSEPH III | Director | Jul 01 '26 | Option Exercise | 39.94 | 11,518 | 460,029 | 22,532 | Jul 06 |
| KLEIN JOSEPH III | Director | Jul 01 '26 | Sale | 79.04 | 11,518 | 910,417 | 11,014 | Jul 06 |
| Baroldi Joseph | EVP, Chief Business Officer | Jun 26 '26 | Option Exercise | 49.19 | 5,635 | 277,180 | 10,304 | Jun 30 |